William W. Hall

TL;DR: The generation of HTLV-I Tax transgenic mice is described using the Lck proximal promoter to restrict transgene expression to developing thymocytes and this model accurately reproduces human disease and will provide a tool for analysis of the molecular events in transformation and for the development of new therapeutics.

TL;DR: It is demonstrated that T helper type 1 and regulatory T cells are induced against the same epitopes on the core protein during HCV infection.

TL;DR: Brazilian neurologists and observers from other countries met recently to discuss and propose a modified model for diagnosing TSP/HAM with levels of ascertainment as definite, probable, and possible, according to myelopathic symptoms, serological findings, and/or detection of HTLV-I DNA and exclusion of other disorders.

TL;DR: To evaluate the role of HTLV‐II in neurological disease, it is confirmed that although rare infection is associated with a disorder clinically similar or identical to HAM/TSP, neurologists should be aware of the potential clinical consequences of this infection.

TL;DR: The European HIV Drug Resistance Panel was established to make recommendations to clinicians and virologists on this topic and to propose quality control measures as mentioned in this paper, and the panel recommended resistance testing for the following indications: i) drug-naive patients with acute or recent infection; ii) therapy failure, including suboptimal treatment response, when treatment change is considered; iii) pregnant HIV-1-infected women and paediatric patients with detectable viral load when treatment initiation or change is considering; and iv) genotype source patient when post-exposure prophylaxis is considered